Instrument Inactif

Autres langues Threshold Pharmaceuticals, Inc. Nasdaq

Actions

US8858072064

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	12/04
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism	09/04
Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	09/04
Molecular Templates, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update	29/03
Molecular Templates, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement	28/03
North American Morning Briefing: Investors Balance AI Hopes with Rate Concerns	18/03
Molecular Templates, Inc. Provides Interim Update	04/03
Molecular Templates, Inc. Provides Interim Update	04/03
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	08/02
Molecular Templates, Inc. Announces Board Changes	17/01
Molecular Templates, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q3 Revenue $6.8M	13/11
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update	13/11
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	02/11
Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	02/11
Molecular Templates to Participate in Upcoming Investor Conferences	01/11
Molecular Templates Names Chief Medical Officer	28/09/23
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer	28/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Threshold Pharmaceuticals, Inc. Nasdaq

Actions

US8858072064

Autres langues

Filtres